Skip to main content
. 2023 Feb 11;27(5):435–444. doi: 10.1007/s10157-023-02318-0

Table 1.

Participants’ characteristics at baseline according to decline in kidney function

Total
(n = 10,547)
Normal eGFR decliner
(n = 10,214)
Rapid eGFR decliner
(n = 333)
Age (years) 53.3 ± 11.6 53.3 ± 11.6 52.0 ± 13.4
Sex (male) 5320 (50.4) 5134 (50.3) 186 (55.9)
BMI (kg/m2) 22.9 ± 2.99 22.9 ± 3.0 23.1 ± 3.2
Systolic blood pressure* (mmHg) 123.8 ± 17.8 123.7 ± 17.8 125.8 ± 18.5
Diastolic blood pressure* (mmHg) 74.8 ± 11.0 74.7 ± 11.0 77.0 ± 11.3
 140/90 mmHg or higher* 1217 (11.5) 1157 (11.3) 60 (18.0)
Hemoglobin (g/dL) 13.9 ± 1.40 13.9 ± 1.39 13.8 ± 1.64
Albumin* (g/dL) 4.51 ± 0.23 4.52 ± 0.23 4.45 ± 0.23
Alanine transferase (IU/L) 18 (14–25) 18 (14–25) 18 (13–25)
Creatinine (mg/dL) 0.71 ± 0.16 0.71 ± 0.16 0.72 ± 0.17
Estimated GFR* (mL/min/1.73 m2) 83.1 ± 10.1 83.1 ± 9.97 84.3 ± 12.8
Uric acid (mg/dL) 5.22 ± 1.23 5.22 ± 1.23 5.22 ± 1.31
Total cholesterol (mg/dL) 203.1 ± 34.8 203.1 ± 34.7 201.4 ± 036.7
HDL cholesterol* (mg/dL) 58.9 ± 15.1 59.0 ± 15.2 55.9 ± 14.3
 Lower than 40 mg/dL 812 (7.7) 786 (7.7) 26 (7.8)
Non-HDL cholesterol (mg/dL) 144.2 ± 35.1 144.2 ± 35.0 145.5 ± 36.3
 170 mg/dL or higher 2390 (22.7) 2309 (22.6) 81 (24.3)
Triglyceride (mg/dL) 96 (69–137) 96 (69–137) 96 (71–142)
 150 mg/dL or higher 2126 (20.2) 2054 (20.1) 72 (21.6)
C-reactive protein (mg/dL) 0.1 (0–0.1) 0.1 (0–0.1) 0.1 (0–0.1)
Fasting plasma glucose (mg/dL) 97 ± 16 97 ± 16 99 ± 22
HbA1c, NGSP (%) 5.4 ± 0.7 5.4 ± 0.7 5.4 ± 1.0
 Potential diabetes mellitus from baseline data 501 (4.8) 478 (4.7) 23 (6.9)
Dyslipidemia on treatment 59 (0.56) 57 (0.6) 2 (0.6)
Hypertension on treatment* 325 (3.1) 301 (2.9) 24 (7.2)
History of stroke 20 (0.19) 19 (0.2) 1 (0.3)
History of ischemic heart disease* 43 (0.41) 39 (0.4) 4 (1.2)

According to the property of each datum, the data are expressed as mean and standard deviation, median and quartile range, or subject number and percentage

*P < 0.05 between normal decliner and rapid decliner